Navigation Links
Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria
Date:5/26/2010

ease, creating an urgent need for new, effective drug treatments as well as preventive measures.

About Restanza

Restanza is a novel, once-a-day, oral antibiotic that is in late stage development for the treatment of adults with mild-to-moderate community-acquired pneumonia ("CABP") and biodefense pathogens. It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections and appears to be effective against penicillin-, macrolide- and fluoroquinolone-resistant bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CABP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure and other high priority biodefense pathogens, including plague and tularemia. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, as well as for use in treating plague and tularemia, but the drug is not yet approved for these or any other indications.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
2. Elekta / Mitsubishi Electric Collaboration Helps Japans Gunma University Heavy Ion Medical Center Launch Advanced Carbon Ion Therapy for Treating Cancer
3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
4. Advanced BioFuels Association Applauds U.S. Sen. Bill Nelsons Leadership as Biofuels Tax Incentives Bill Is Introduced
5. Advanced Life Sciences to Host 2010 First Quarter Financial Results Conference Call and Webcast
6. Upgrade to Advanced Photon Source Announced by DOE
7. Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications
8. Atherotechs Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010
9. Citius Tech Launches BI-Clinical MUSE for Advanced "Meaningful Use" Reporting and Data Submission, and Performance Management for Healthcare ISVs
10. Advanced Instruments Signs License and Sensor Development Agreement With Cantimer, Inc.
11. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... Mass. , May 20, 2015  Haemonetics Corporation ... Concannon , President & CEO, will present at The ... York on June 1 st , 2015 ... may access Mr. Concannon,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global ...
(Date:5/20/2015)... May 20, 2015  Resolution Bioscience announced today the ... ALK TM , a blood-based liquid biopsy for an ... carcinoma (NSCLC), the most common form of this cancer. ... guide patients to personalized therapies and direct them into ... The Department of Health, the CLIA authority in ...
(Date:5/20/2015)... Carolina , 20. Mai 2015 ... für klinische Logistik (Clinical Logistics Organization/CLO) ... Geschäftsjahr 2014, das am 31. Dezember ... Unternehmen hat die Marktentwicklung übertroffen und ... - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 The ... based not-for-profit organization, is pleased to announce they are ... Trials Day. These donations represent the effort and commitment ... at the GGI partner sites in 2014. , ... the greater good of clinical trial participation, GGI supports ...
Breaking Biology Technology:Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... of the 1962 Nobel Prize with Francis Crick and Maurice ... DNA, will present "Curing Incurable Cancer" and attend other events ... the James Graham Brown Cancer Center at the University of ... 5, at the Brown Theater, 315 W. Broadway, Louisville. Admission ...
... early stages of a major cause of failure in joint ... avoid additional surgery. More than 1.5 million total joint replacement ... is 90 per cent, almost 10 per cent of implants ... journal Molecular Pharmaceutics . Dong Wang and colleagues ...
... do not rely on oxygen may have played an important ... to a theory that UChicago researcher Albert Colman is testing ... Siberia. He has found that bacteria at the site ... that scientists must take into account as they attempt to ...
Cached Biology News:UofL hosts address by Nobel Laureate, DNA structure co-discoverer James Watson 2Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
...
... analysis & visualization software. ... multiple samples. Combine Sequest ... increased confidence. Get more ... from your MS/MS experiments.14 ...
Biology Products: